Baudax Bio, Inc. (BXRX)

NASDAQ: BXRX · IEX Real-Time Price · USD
1.18
0.07 (6.31%)
At close: May 16, 2022 4:00 PM
1.20
0.02 (1.69%)
After-hours:May 16, 2022 7:35 PM EDT
Market Cap7.58M
Revenue (ttm)1.30M
Net Income (ttm)-18.09M
Shares Out6.42M
EPS (ttm)-10.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume104,097
Open1.18
Previous Close1.11
Day's Range1.11 - 1.19
52-Week Range0.94 - 32.87
Beta2.24
AnalystsBuy
Price Target8.16 (+591.5%)
Earnings DateMay 5, 2022

About BXRX

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intran...

IndustryBiotechnology
Employees80
Stock ExchangeNASDAQ
Ticker SymbolBXRX
Full Company Profile

Financial Performance

In 2021, Baudax Bio's revenue was $1.08 million, an increase of 119.07% compared to the previous year's $493,000. Losses were -$19.77 million, -74.02% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for BXRX stock is "Buy." The 12-month stock price forecast is 8.16, which is an increase of 591.53% from the latest price.

Price Target
$8.16
(591.53% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders

Annual Meeting to be reconvened on May 18, 2022 Annual Meeting to be reconvened on May 18, 2022

1 week ago - GlobeNewsWire

Baudax Bio Reports First Quarter 2022 Financial Results and Business Highlights

ANJESO ® Net Product Revenue Up 113% Compared to Same Period in Prior Year; Sixth Consecutive Quarter of Demand Growth

1 week ago - GlobeNewsWire

Baudax Bio to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that it will report first ...

2 weeks ago - GlobeNewsWire

What Makes Baudax Bio, Inc. (BXRX) a New Strong Buy Stock

Baudax Bio, Inc. (BXRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago - Zacks Investment Research

Here's Why Baudax Bio, Inc. (BXRX) Could be Great Choice for a Bottom Fisher

Baudax Bio, Inc. (BXRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mea...

1 month ago - Zacks Investment Research

Baudax Bio Reports 2021 Fourth Quarter and Annual Financial Results

ANJESO End User Demand and Revenue Increases Four Quarters In A Row

2 months ago - GlobeNewsWire

Baudax Bio Regains Compliance with NASDAQ Listing Requirements

MALVERN, Pa., March 07, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced...

2 months ago - GlobeNewsWire

Baudax Bio Announces Pricing of $10.0 Million Public Offering

MALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on commercializing and developing innovative products fo...

2 months ago - GlobeNewsWire

Baudax Bio Announces Proposed Public Offering of Securities

MALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on commercializing and developing innovative products fo...

2 months ago - GlobeNewsWire

Baudax Bio Announces 1-for-35 Reverse Stock Split

MALVERN, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today annou...

3 months ago - GlobeNewsWire

Can These Penny Stocks Climb This Week? 4 To Watch Right Now

Are these penny stocks on your watchlist for next week? The post Can These Penny Stocks Climb This Week?

Other symbols:ARDSWIMI
3 months ago - PennyStocks

3 Penny Stocks Under $1 For You List This Week

Penny stocks to watch today The post 3 Penny Stocks Under $1 For You List This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:AIRIMRKR
3 months ago - PennyStocks

Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

MALVERN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today annou...

4 months ago - GlobeNewsWire

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care sett...

4 months ago - GlobeNewsWire

Baudax Bio Announces $4.2 Million Registered Direct Offering

MALVERN, Pa., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care sett...

4 months ago - GlobeNewsWire

Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today annou...

6 months ago - GlobeNewsWire

Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000

BX-1000 Completes Dose-Escalation Study; Was Generally Well Tolerated and Rapidly Achieved Muscle Paralysis, Along with Complete Spontaneous Recovery

6 months ago - GlobeNewsWire

Baudax Bio Reports Third Quarter 2021 Financial Results and Business Highlights

ANJESO ® Revenue Up 40% in Q3 2021 over Q2 2021 and Up Over 300% in Q3 2021 over Q3 2020

6 months ago - GlobeNewsWire

Baudax Bio to Present at the NobleCon Pain Management Investor Forum

MALVERN, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today anno...

7 months ago - GlobeNewsWire

Baudax Bio to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

MALVERN, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today ann...

8 months ago - GlobeNewsWire

Baudax Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today ann...

8 months ago - GlobeNewsWire

5 Penny Stocks Insiders Are Buying

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...

Other symbols:AMPYCLXTRSLS
8 months ago - Benzinga

Do Options Traders Know Something About Baudax Bio (BXRX) Stock We Don't?

Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

Baudax Bio: Q2 Earnings Insights

Shares of Baudax Bio (NASDAQ:BXRX) rose 0.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 87.79% year over year to ($0.21), which missed the ...

9 months ago - Benzinga

Baudax Bio Reports Second Quarter 2021 Financial Results and Highlights

Total Number of ANJESO ® Vials Sold to End-Users in the Second Quarter 2021 Match Total Vials Sold for the Full Year 2020

9 months ago - GlobeNewsWire